- Home
- ATNM vs CNF Comparison
ATNM vs CNF Comparison
Compare ATNM & CNF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ATNM | CNF |
|---|---|---|
| Founded | 2000 | 1999 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.1M | 43.5M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | ATNM | CNF |
|---|---|---|
| Price | $1.36 | $6.32 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $4.00 | N/A |
| AVG Volume (30 Days) | ★ 182.4K | 6.9K |
| Earning Date | 11-14-2025 | 08-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $90,000.00 | ★ $50,241,013.00 |
| Revenue This Year | N/A | $252.34 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 11.11 | N/A |
| 52 Week Low | $1.03 | $2.36 |
| 52 Week High | $2.41 | $13.90 |
Technical Indicators
Market Signals| Indicator | ATNM | CNF |
|---|---|---|
| Relative Strength Index (RSI) | 41.07 | 57.98 |
| Support Level | $1.57 | $6.00 |
| Resistance Level | $1.72 | $6.49 |
| Average True Range (ATR) | 0.10 | 0.22 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 0.00 | 63.29 |
Price Performance
Historical ComparisonAbout ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.
About CNF CNFinance Holdings Limited each representing twenty (20)
CNFinance Holdings Ltd is an equity loan service provider. It focuses on the development of small and micro-enterprises. It generates revenue in the form of interest and financing service fees on loans and interest on deposits with banks. Its primary target borrower segment is MSE owners who own real properties in Tier 1 and Tier 2 cities in China. Geographically, it has an operation in PRC.